Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. All Rights Reserved. Entasis Therapeutics Holdings Inc. is followed by the analysts listed above. NasdaqGM:ETTX Income Statement, December 19th 2019. As of July 15th, there was short interest totalling 164,200 shares, an increase of 827.7% from the June 30th total of 17,700 shares. This is 7.42% more than the trading day before Friday, 12th Mar 2021. Entasis Therapeutics Holdings Inc. Common Stock (ETTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. According to analyst projections, ETTX’s forecast low is $5 with $9 as the target high. Executive Summary. Entasis Therapeutics Holdings Inc. (ETTX) estimates and forecasts Entasis Therapeutics Holdings Inc. (ETTX) shares on Friday’s trading session, dropped -1.17 percent to see the stock exchange hands at $3.39 per unit. Earnings for Entasis Therapeutics are expected to grow in the coming year, from ($2.49) to ($1.33) per share. Factset: FactSet Research Systems Inc.2019. On average, Wall Street analysts predict that . Earnings and Valuation of Entasis Therapeutics (NASDAQ:ETTX. Get the latest Entasis Therapeutics (ETTX) stock price quote with real-time news, financials, charts and other important investing information. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Stock Price Forecast The 7 analysts offering 12-month price forecasts for Entasis Therapeutics Holdings Inc have a median target of 6.50, with a high estimate of 9.00 and a low estimate of 5.00. © 2834 . Entasis Therapeutics Holdings Inc Stock Price Forecast, "ETTX" Predictons for2021 Entasis Therapeutics ETTX WideScreen charts, DMA,SMA,EMA technical analysis, forecast prediction, by indicators ADX,MACD,RSI,CCI NASDAQ stock exchange. The average price target represents a 229.13% upside from the last price of $2.04. Entasis Therapeutics Holdings Inc. (ETTX) estimates and forecasts If you had invested in Entasis Therapeutics Holdings stock at $10.66, your return over the last 2 years would have been -73.45%, for an annualized return of -48.48%. 10 day averaged volume of Entasis Therapeutics is 475820 Wall Street Stock Market & Finance report, prediction for the future: You'll find the Entasis Therapeutics Holdings share forecasts, stock quote and buy / sell signals below. Entasis Therapeutics Holdings Inc (ETTX) Stock Forecast By Analysts Strong Buy Analysts Recommendations for Entasis Therapeutics Holdings Inc ( ETTX ) is based on 13 Institutional Analyst Ratings where 69.23 % are on Strong Buy, 23.08 % on Moderate Buy, 7.69 % remains on Hold, 0.00 % are on Moderate Sell and 0.00 % are on Strong Sell. Read market forecasts, ETTX financials, economic background and market news Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Earnings estimates and surprises for Entasis Therapeutics Holdings Inc (ETTX) are an important tool used to evaluate the company's overall strength and value of the stock. ETTX 2.92 0.12 (3.95%) Post-Market 0.01 (0.34%) 2,145. This price target is based on 7 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. Importantly, its cash burn was US$46m over the trailing twelve months. The median estimate represents a +142.54% increase from the last price of 2.68. CNN Sans™ & © 2016 Cable News Network. The 12-month stock price forecast is 6.50, which is an increase of 129.68% from the latest price. Complete technical analysis of Entasis Therapeutics (ETTX) by charts plus indicators, forecast predictions and share price targets for Entasis Therapeutics (ETTX) Entasis Therapeutics trades in USA in Health Care sector. Therefore, from September 2020 it had roughly 16 months of cash runway. © 2020 Cable News Network. Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. The company's product pipeline consists of etx2514sul, zoliflodacin, etx0282cpdp and nbp program which are in clinical stage. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Please note that any opinions, estimates or forecasts regarding Entasis Therapeutics Holdings Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Entasis Therapeutics Holdings Inc. or its management. What this means: InvestorsObserver gives Entasis Therapeutics Holdings In (ETTX) an overall rank of 50, which is below average. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. ... Common Stock, $0.001 par value . What is ETTX's forecast return on assets (ROA) for 2021-2024? To hit the forecast high, the stock’s price needs a +165.49% upsurge from its current level, while the stock would need to tank 47.49% for it to hit the projected low. In 2023, ETTX is forecast to generate $-29,201,972 in earnings, with the lowest earnings forecast at $-41,756,091 and the highest earnings forecast at $-16,647,853. In the short term (2weeks), ETTX's stock price should outperform the market by 6.46%.During that period the price should oscillate between -10.77% and +17.63%. Entasis Therapeutics Earnings Estimates and Actuals by Quarter stock was originally listed at a price of $10.66 in Sep 26, 2018. Entasis Therapeutics stock price prediction is an act of determining the future value of Entasis Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation.The successful prediction of Entasis Therapeutics stock future price could yield a significant profit. Gonorrhea Therapeutics Market Projection By Dynamics, Trends, Predicted Revenue, Regional Segmented, Outlook Analysis & Forecast Till 2031 Published: Feb. 8, 2021 at 11:11 a.m. Entasis Therapeutics Ltd PRIVATE Updated Mar 16, 2021 9:07 PM. Earnings and Valuation of Entasis Therapeutics (NASDAQ:ETTX. What's Happening With Entasis Therapeutics Holdings Inc Stock Today? 8 Wall Street analysts have issued ratings and price targets for Entasis Therapeutics in the last 12 months. “We are very pleased with the continued progress made during the first … Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Entasis Therapeutics Holdings Inc. ETTX was a big mover last session, as the company saw its shares rise more than 5% on the day. Entasis Therapeutics Holdings In is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Watch. What is ETTX's earnings growth forecast for 2021-2023? Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. We can readily understand why investors are attracted to unprofitable companies. Entasis Therapeutics Holdings Inc (NASDAQ:ETTX)’s stock price gapped up prior to trading on Wednesday after an insider bought additional shares in the company. The move came on … Earnings for Entasis Therapeutics are expected to grow in the coming year, from ($2.49) to ($1.33) per share. Entasis Therapeutics Holdings, Inc. … The average price target represents a 99.24% upside from the last price of $3.37. Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com. Further, Entasis Therapeutics Holdings Inc. (ETTX) has a beta value of 0, and an average true range (ATR) of 0.17. The average price target is $6.71, with a high forecast of $9.00 and a low forecast of $5.00. Entasis Therapeutics Holdings Inc. produces, researches and develops antibacterial therapies and drugs through its subsidiaries. ETTX stock forecast Our latest prediction for Entasis Therapeutics Holdings Inc's stock price was made on the June 11, 2020 when the stock price was at 2.71$.. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. Entasis Therapeutics ETTX operates under Health Care sector & deals in Major Pharmaceuticals . 8 brokers have issued twelve-month price objectives for Entasis Therapeutics' stock. ETTX stock forecast Our latest prediction for Entasis Therapeutics Holdings Inc's stock price was made on the June 11, 2020 when the stock price was at 2.71$.. What is ETTX's forecast return on equity (ROE) for 2021-2024? View Entasis Therapeutics Holdings Inc price, streaming chart and supplemental info. A high-level overview of Entasis Therapeutics Holdings Inc. (ETTX) stock. Entasis Therapeutics ETTX Current Price 03 … Entasis Therapeutics Holdings Inc (ETTX) Stock Forecast By Analysts Strong Buy Analysts Recommendations for Entasis Therapeutics Holdings Inc ( ETTX ) is based on 13 Institutional Analyst Ratings where 69.23 % are on Strong Buy, 23.08 % on Moderate Buy, 7.69 % remains on Hold, 0.00 % are on Moderate Sell and 0.00 % are on Strong Sell. Is Entasis Therapeutics Holdings Stock a good buy in 2021, according to Wall Street analysts? Their average twelve-month price target is $6.71, predicting that the stock has a possible upside of 129.94%. Furthermore, Entasis Therapeutics Holdings Inc. (ETTX)’s beta value is 0, and its average true range (ATR) is 0.26. What is ETTX's revenue growth forecast for 2022-2024? Only 27.55% of the stock of Entasis Therapeutics is held by institutions. Entasis Therapeutics Holdings (ETTX) stock price prediction is 0 USD. Entasis Therapeutics Holdings's share price could stay at $6.33 by Sep 9, 2021. This free interactive report on Entasis Therapeutics Holdings's balance sheet strength is a great place to start, if you want to investigate the stock further.. A Different Perspective. Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. To hit the forecast high, the stock’s price needs a +165.49% upsurge from its current level, while the stock would need to tank 47.49% for it to hit the projected low. Entasis Therapeutics Holdings Inc (ETTX) stock is lower by -8.84% while the S&P 500 has gained 1.04% as of 1:25 PM on Thursday, Sep 24. WALTHAM, Mass., May 07, 2020 -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. Executive Summary. Most stock quote data provided by BATS. Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. Shares in Entasis Therapeutics Holdings Inc are currently priced at $3.15. Only 15.40% of the stock of Entasis Therapeutics is held by insiders. Find real-time ETTX - Entasis Therapeutics Holdings Inc stock quotes, company profile, news and forecasts from CNN Business. Analysts have given the company’s stock an average 52-week price target of $6.5, forecast between a low of $5 and high of $9. All times are ET. Entasis Therapeutics Holdings stock forecast & analyst price target predictions based on a number of analysts offering 12-months price targets for ETTX in the last 3 months. ... the average rating for ETTX stock is "Buy." Entasis Therapeutics Holdings (NASDAQ: ETTX) is owned by 35.83% institutional shareholders, 128.70% Entasis Therapeutics Holdings insiders, and 0.00% retail investors. This price target is based on 7 analysts offering 12 month price targets for Entasis Therapeutics in the last 3 months. Given that the market gained 30% in the last year, Entasis Therapeutics Holdings shareholders might be miffed that they lost 16%. Furthermore, Entasis Therapeutics Holdings Inc. (ETTX)’s beta value is 0, and its average true range (ATR) is 0.26. Menu. The average Entasis Therapeutics Holdings stock price prediction forecasts a potential downside of N/A from the current ETTX share price of $3.04. Entasis Therapeutics Holdings Inc. Common Stock (ETTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Based on an average daily volume of 176,800 shares, the days-to-cover ratio […] The Average True Range (ATR) for Entasis Therapeutics Holdings Inc. is set at 0.08 The Price to Book ratio for the last quarter was 0.88. Entasis Therapeutics Holdings Inc (ETTX) stock is lower by -8.84% while the S&P 500 has gained 1.04% as of 1:25 PM on Thursday, Sep 24. ETTX has fallen -$0.22 from the previous closing price of $2.49 on volume of 119,118 shares. All rights reserved. Entasis Therapeutics Holdings. Skip to content. Only 27.55% of the stock of Entasis Therapeutics is held by institutions. According to present data Entasis Therapeutics Holdings's ETTX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Stock Price Forecast The 7 analysts offering 12-month price forecasts for Entasis Therapeutics Holdings Inc have a median target of 6.50, with a high estimate of 9.00 and a low estimate of 5.00. Disclaimer. ET Comments Investors can use this forecasting interface to forecast Entasis Therapeutics historical stock prices and determine the direction of Entasis Therapeutics Holdings's future trends based on various well-known forecasting models. All rights reserved. What is ETTX's Earnings Per Share (EPS) forecast for 2021-2023? Notably, analysts forecast that Entasis Therapeutics Holdings will break even (at a free cash flow level) in about 4 years. Find out how RiskGrades TM can measure the financial risk of Entasis Therapeutics Holdings Inc. (ETTX) compared to other stocks using the stock analysis below. Entasis Therapeutics Holdings, Inc. … The median estimate represents a +162.10% increase from the last price of 2.48. At that level they are trading at 0.106% discount to the analyst consensus target price of 0.00. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. No recent news for Entasis Therapeutics Holdings Inc. Enter a … What's Happening With Entasis Therapeutics Holdings Inc Stock Today? Find the latest Entasis Therapeutics Holdings I (ETTX) stock quote, history, news and other vital information to help you with your stock trading and investing. ETTX: Get the latest Entasis Therapeutics stock price and detailed information including ETTX news, historical charts and realtime prices. On average, they anticipate Entasis Therapeutics' share price to reach $6.71 in the next year. The Entasis … Watch. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sc… ETTX . As at September 2020, Entasis Therapeutics Holdings had cash of US$61m and no debt. WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2020 financial results and provided a business update. ETTX's Return on Equity is forecast to be low in 3 years (-18.2%); analysts are not confident in the firm's ability to efficiently generate return on equity, ETTX is forecast to generate lower Return on Assets (-16.19%) than the US Biotechnology industry average (22.48%), On average, Wall Street analysts predict that.